Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Pharma’s return on research and development investment has risen sharply, with GLP-1 therapies for obesity and diabetes ...

The rise of GLP-1 drugs like Ozempic are changing consumer food waste patterns both at home and in restaurant settings.

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Gallagher Re, a reinsurance brokerage and risk management services provider, has released a report on the impact of GLP-1 ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

More recently, Ascletis has unveiled and quickly advanced a weight-loss pipeline that features oral and subcutaneous formulations of a GLP-1 receptor agonist. Ascletis formalized the shift in its ...

up from 4.1% in 2023. Without GLP-1s, the returns for R&D would have dropped to 3.8% in 2024. The value from R&D comes from products that are still in the pipeline but in late stages of ...